CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study.
CINSARC
chemotherapy
outcome
prognostication
sarcoma
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
12
04
2022
received:
11
01
2022
accepted:
20
06
2022
pubmed:
19
7
2022
medline:
1
2
2023
entrez:
18
7
2022
Statut:
ppublish
Résumé
The Complexity INdex in SARComas (CINSARC) is a transcriptional signature derived from the expression of 67 genes involved in mitosis control and chromosome integrity. This study aims to assess CINSARC value of in an independent series of high-risk patients with localized soft tissue sarcoma (STS) treated with preoperative chemotherapy within a prospective, randomized, phase III study (ISG-STS 1001). Patients with available pre-treatment samples, treated with 3 cycles of either standard (ST) preoperative or histotype-tailored (HT) chemotherapy, were scored according to CINSARC (low-risk, C1; high-risk, C2). The 10-year overall survival probability (pr-OS) according to SARCULATOR was calculated, and patients were classified accordingly (low-risk, Sarc-LR, 10-year pr-OS>60%; high-risk, Sarc-HR, 10-year pr-OS<60%). Survival functions were estimated using the Kaplan-Meier method and compared using log-rank test. Eighty-six patients were included, 30 C1 and 56 C2, 49 Sarc-LR and 37 Sarc-HR. A low level of agreement between CINSARC and SARCULATOR was observed (Cohen's Kappa = 0.174). The 5-year relapse-free survival in C1 and C2 were 0.57 and 0.55 (p = 0.481); 5-year metastases-free survival 0.63 and 0.64 (p = 0.740); 5-year OS 0.80 and 0.72 (p = 0.460). The 5-year OS in C1 treated with ST and HT chemotherapy was 0.84 and 0.76 (p = 0.251) respectively; in C2 treated it was 0.72 and 0.70 (p = 0.349). The 5-year OS in Sarc-LR treated with S and HT chemotherapy was 0.80 and 0.82 (p = 0.502) respectively; in Sarc-HR it was 0.70 and 0.61 (p = 0.233). Our results, although constrained by the small size of the series, suggest that CINSARC has weak prognostic power in high-risk, localized STS treated with neoadjuvant chemotherapy.
Sections du résumé
BACKGROUND
The Complexity INdex in SARComas (CINSARC) is a transcriptional signature derived from the expression of 67 genes involved in mitosis control and chromosome integrity. This study aims to assess CINSARC value of in an independent series of high-risk patients with localized soft tissue sarcoma (STS) treated with preoperative chemotherapy within a prospective, randomized, phase III study (ISG-STS 1001).
PATIENTS AND METHODS
Patients with available pre-treatment samples, treated with 3 cycles of either standard (ST) preoperative or histotype-tailored (HT) chemotherapy, were scored according to CINSARC (low-risk, C1; high-risk, C2). The 10-year overall survival probability (pr-OS) according to SARCULATOR was calculated, and patients were classified accordingly (low-risk, Sarc-LR, 10-year pr-OS>60%; high-risk, Sarc-HR, 10-year pr-OS<60%). Survival functions were estimated using the Kaplan-Meier method and compared using log-rank test.
RESULTS
Eighty-six patients were included, 30 C1 and 56 C2, 49 Sarc-LR and 37 Sarc-HR. A low level of agreement between CINSARC and SARCULATOR was observed (Cohen's Kappa = 0.174). The 5-year relapse-free survival in C1 and C2 were 0.57 and 0.55 (p = 0.481); 5-year metastases-free survival 0.63 and 0.64 (p = 0.740); 5-year OS 0.80 and 0.72 (p = 0.460). The 5-year OS in C1 treated with ST and HT chemotherapy was 0.84 and 0.76 (p = 0.251) respectively; in C2 treated it was 0.72 and 0.70 (p = 0.349). The 5-year OS in Sarc-LR treated with S and HT chemotherapy was 0.80 and 0.82 (p = 0.502) respectively; in Sarc-HR it was 0.70 and 0.61 (p = 0.233).
CONCLUSIONS
Our results, although constrained by the small size of the series, suggest that CINSARC has weak prognostic power in high-risk, localized STS treated with neoadjuvant chemotherapy.
Identifiants
pubmed: 35848358
doi: 10.1002/cam4.5015
pmc: PMC9883440
doi:
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase III
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1350-1357Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Lancet Oncol. 2017 Jun;18(6):812-822
pubmed: 28499583
NPJ Breast Cancer. 2021 May 5;7(1):48
pubmed: 33953185
Cancer. 2022 Jan 01;128(1):85-93
pubmed: 34643947
Nat Med. 2010 Jul;16(7):781-7
pubmed: 20581836
Clin Cancer Res. 2012 Feb 1;18(3):826-38
pubmed: 22167411
Eur J Cancer. 2016 Apr;57:104-11
pubmed: 26916546
Cancer Med. 2023 Jan;12(2):1350-1357
pubmed: 35848358
Ann Oncol. 2018 Aug 1;29(8):1828-1835
pubmed: 29860427
Ann Oncol. 2019 Jan 1;30(1):153-155
pubmed: 30335133
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
Clin Cancer Res. 2020 Feb 15;26(4):855-861
pubmed: 31796515
Mod Pathol. 2018 May;31(5):816-828
pubmed: 29327710
Lancet. 2002 Apr 13;359(9314):1309-10
pubmed: 11965278
J Clin Oncol. 2013 Feb 10;31(5):608-15
pubmed: 23319690
Pediatr Blood Cancer. 2021 Jul;68(7):e28987
pubmed: 33751795
BMC Cancer. 2020 Jul 31;20(1):716
pubmed: 32736540
Sci Rep. 2017 Jul 14;7(1):5480
pubmed: 28710396